Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 10, 2021

Effect of Arjun Chāl on cardiovascular risk factors – a randomized controlled clinical trial

  • Saima Saleem , Abdul Haseeb Ansari ORCID logo EMAIL logo and Aysha Ansari



Cardiovascular diseases have a multifaceted, it causes modern epidemic; Recognizing in the risk factor stage, is crucial, given the risk of progression to cardiovascular disease. Ibn Sīnā, described CVDs as a resultant of gradual derangement of Quwwat ghādhiya (Nutritive faculty); in which management with ghidhā’ (diet), tadābīr (regimens), dawā’ (drug) has been received. To evaluate the effect of Arjun Chāl (Terminalia arjuna) in CVD risk factors. And to evaluate the drug safety.


This is a randomized controlled clinical trial. Total 120 patients were screened at OPD of NIUM hospital, Bangalore during 2018–19, only 48 patients fulfilled the inclusion criteria and signed written informed consent and their detailed medical history was recorded. Arjun Chāl powder (5 gm BD) for eight weeks administered in test group (n=24), Amlodipine (5 mg) and Atorvastatin (10 mg) once a day for same duration administered in control group (n=24). Efficacy of the drug assessed by the Lipid profile, BP and BMI; lipid profile were performed at baseline and at 8 weeks, while BP and BMI performed at baseline, 15, 30, 45, and 60th day intervals. Study was completed by 40 patients. The results of both the therapies were then compared and statistically analyzed.


Totally, both groups reduces assessment parameters i.e. statistically highly significant (p<0.001). Test group showed greater reduction in terms of all assessment parmeters. But, the difference between both the groups was statistically non-significant p>0.05.


Both test and control drugs were effective, but Arjun Chāl had a slight edge over amlodipne and atorvastatin, and was found to be safe and well tolerated. It has a cardio protective potential and hence effective to delay/prevent CVD in patient with cardiovascular risk factor.Keywords: Unani System of Medicine; T. arjuna; Arjun Chāl; Efficacy; Safety; Cardiovascular risk factor.

Corresponding author: Abdul Haseeb Ansari, Tahaffuzi wa Samaji Tib (Preventive and Social Medicine), National Institute of Unani Medicine, Kottigepalya, Magadi Main Road, 560091 Bangalore, Karnataka, India, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.


1. Anonymous. FACT SHEET- hypertension World Heart Federation. Geneva, Switzerland: WHO; 2017.Search in Google Scholar

2. Park, K. Park’s textbook of preventive and social medicine, 24th ed. Jabalpur: Banarsidas Bhanot; 2017:380–91 pp.Search in Google Scholar

3. Ejim, EC, Okafor, CI, Emehel, A, Mbah, AU, Onyia, U, Egwuonwu, T, et al.. Prevalence of cardiovascular risk factors in the middle-aged and elderly population of a Nigerian rural community. J Trop Med 2011;2011:1–6. in Google Scholar

4. Chauhan, S, Aeri, TB. Prevalence of cardiovascular diseases in India and its economic impact – a review. Int J Sci Res Publ 2013;3:1–4.Search in Google Scholar

5. Kasper, DL, Fauci, AS, Hauser, SL, Longo, DL, Jameson, JL, Loscalzo, JL. Harrison’s manual of medicine, 19th ed. New York: McGraw-Hill Education; 2016:2226–23 pp.Search in Google Scholar

6. Goldman, L, Ausiello, D. Cecil text book of medicine, 25th ed. New Delhi: Ajanta Offset; 2016, vol 2:259–62 pp.Search in Google Scholar

7. O’Donnell, CJ, Elosua, R. Cardiovascular risk factors. Insights from framingham heart study. Rev Esp Cardiol 2008;61:299–310. in Google Scholar

8. AL-Nooh, AA, Alajmi, AAA, Wood, D. The prevalence of cardiovascular disease risk factors among employees in the Kingdom of Bahrain between October 2010 and March 2011: a cross-sectional study from a workplace health campaign. Cardiol Res Pract 2014;2014:1–9. in Google Scholar

9. Anonymous. FACT SHEET- cardiovascular diseases (CVDs). Geneva, Switzerland: WHO; 2017.Search in Google Scholar

10. Anonymous. Prevention of cardiovascular disease guidelines for assessment and management of cardiovascular risk. Geneva, Switzerland: WHO; 2007.Search in Google Scholar

11. Rūshd, I. Kitāb al-Kulliyyāt (Urdu translation). Lahore: Maktaba Danyal; 2015:159–75 pp.Search in Google Scholar

12. Ibn Sīnā Abū ‘Alī al-Ḥusayn ibn ‘Abd Allāh. Al Qānūn fi‘l Ṭibb (Urdu translation by Ghulām Ḥasnayn Kintūrī). New Delhi: Idara Kitabus Shifa; YNM; 2010:197–201 pp.Search in Google Scholar

13. Majūsī ‘Ali ibn ‘Abbās. Kāmil al-Ṣanā‘a (Urdu translation by Ghulām Ḥasnayn Kintūrī). New Delhi: Idara Kitabus Shifa; 2010:497–9, 548–50 pp.Search in Google Scholar

14. Ṭabarī ‘Alī bin Sahal Rabban. Firdaws al-Hikmā. New Delhi: Idara Kitabus Shifa; 2010. p. 112–7, 124–31, 212–4, 471–2 pp.Search in Google Scholar

15. Jurjānī Shaf al-Dīn Ismā‘īl. Dhakhīra Khawārizm Shāhī (Urdu translation by Khan ḤḤ). . New Delhi: Idara Kitabus Shifa; 2010, vol 1, 2, 6:19–20, 24–8, 40–1, 44–5, 305–13 pp.Search in Google Scholar

16. Rāzī Abū Bakr Muḥammad ibn Zakariyyā. Kitāb al-Manṣūrī. New Delhi: CCRUM; 1991:72–8, 223 pp.Search in Google Scholar

17. Ibn Sīnā Abū ‘Alī al-Ḥusayn ibn ‘Abd Allāh. Kulliyyāt Qānūn (Tarjama-o-Sharaḥ by Kabīr al-Dīn Ḥakīm Muḥammad). Part 1 & 2. Lahore, Pakistan: Sheikh Basheer and Sons Publications; 1930:222 p.Search in Google Scholar

18. Kirmānī Nafīs bin ‘Iwaḍ. Kulliyyāt-i-Nafīsī: (Tarjama-o-Sharaḥ by Kabīr al-Dīn Ḥakīm Muḥammad). New Delhi: Idara Kitabus Shifa; 2010, vol 1:471 p.Search in Google Scholar

19. Amalraj, A, Gopi, S. Medicinal properties of Terminalia arjuna (Roxb.) wight & arn: a review. J Tradit Complementary Med 2017;7:65–78. in Google Scholar

20. Al-Ghanī Najm. Khaza’in al-Adwiya. New Delhi: Idara Kitabus Shifa; 2010:217 p.Search in Google Scholar

21. Dwivedi, S, Chopra, D. Revisiting Terminalia arjuna – an ancient cardiovascular drug. J Tradit Complementary Med 2014;4:224–31. in Google Scholar

22. Suganthy, N, Muniasamy, S, Archunan, G. Safety assessment of methanolic extract of Terminalia chebula fruit, Terminalia arjuna bark and its bioactive constituent 7-methyl gallic acid: in vitro and in vivo studies. Regul Toxicol Pharmacol 2018;92:347–57. in Google Scholar

23. Panigrahi, T, Vishwas, S, Dash, D. A herbal approach to obesity management: a review. Asian J Pharmaceut Educ Res 2017;6:1–15.Search in Google Scholar

24. Anonymous. High blood cholesterol, ATP III guideline at A – glance quick desk reference. National Institutes of Health National Heart, Lung, and Blood Institute; 2013. Available from: in Google Scholar

25. Deepak, BSR, Lakshamiprasad, J, Girish, KJ, Prakash, N. Randomized controlled, open labelled study of a herbal preperation, lekhaneeya mahakashaya ghanavati in dyslipidemia patients. J Ayurveda Holist Med 2015;3:1–23.Search in Google Scholar

26. Suresh, KP, Chandrashekara, S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 2012;5:1–8. in Google Scholar

27. Rosner, B. Fundamentals of biostatistics, 5th ed. Duxbury: Pacific Gove, CA; 2000:80–240 pp.Search in Google Scholar

28. Riffenburgh, RH. Statistics in medicine, 2nd ed. Cambridge, MA, USA: Academic Press; 2005:85–125 pp.Search in Google Scholar

29. Sunder Rao, PSS, Richard, J. An introduction to biostatistics, a manual for students in health sciences, 4th ed. New Delhi: Prentice Hall of India; 2006:86–160 pp.Search in Google Scholar

30. Sharma, S, Sharma, D, Agarwal, N. Diminishing effect of arjuna tree (Terminalia arjuna) bark on the lipid and oxidative stress status of high fat high cholesterol fed rats and development of certain dietary recipes containing the tree bark for human consumption. Res Pharm 2012;2:1–9.Search in Google Scholar

31. Mandal, S, Patra, A, Samanta, A, Roy, S, Mandal, A, Mahapatra, TD, et al.. Analysis of phytochemical profile of Terminalia arjuna bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed 2013;3:960–6. in Google Scholar

32. al-Din, K, Muḥammad, Ḥ. Makhzan al-Mufradāt. New Delhi: Idara Kiatabus Shifa; 2002:52–3 pp.Search in Google Scholar

33. Ajay Raja, S, Sivakumar, K, Sujatha, K. Prevalence of dyslipidemia in South Indian adults: an urban rural comparision. Int J Community Med Public Health 2016;3:2205.Search in Google Scholar

34. Al-Qamarī Abū al-Manṣūr ibn Nūḥ. Ghinā Munā. New Delhi: CCRUM; 2008:384–90 pp.Search in Google Scholar

35. Cooper, C. The influence of cardiovascular disease risk factors on exercise participation; 2017:1–87. Available from: in Google Scholar

36. Goyal, A, Yusuf, S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006;124:235–44.Search in Google Scholar

37. Prakash, V, Kumar Sehgal, V, Bajaj, VK, Singh, H. To compare the effects of Terminalia arjuna with Rosuvastatin on total cholesterol and low density lipoprotein cholesterol. Int J Med Dent Sci 2016;5:1056–66. in Google Scholar

38. Maulik, SK, Katiyar, CK. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. Curr Pharm Biotechnol 2010;10:855–60.10.2174/138920110793262051Search in Google Scholar PubMed

39. Kapoor, D, Vijayvergiya, R, Dhawan, V. Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical & safety evaluation. J ethno 2014;155:1029–45. in Google Scholar PubMed

40. Anonymous. The Unānī Pharamacopoeia of India. Part-1. New Delhi: Govt. of India MH & FW, Dept. of AYUSH; 2007, vol IV:13–4 pp.Search in Google Scholar

41. al-Din, K, Muḥammad, Ḥ. Bustān al-Mufradāt. New Delhi: Idara Kitabus Shifa; 2002:62–3 pp.Search in Google Scholar

Received: 2020-10-31
Accepted: 2021-01-30
Published Online: 2021-05-10

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 7.12.2023 from
Scroll to top button